MktsMarkets

Akebia Therapeutics, Inc.
NASDAQ: AKBAKey statistics
AKBA News
Stories mentioning AKBA from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 53,544 | 57,622 | 58,766 | 62,472 | 57,336 | 46,497 | 37,428 | 43,648 |
| Cost of Goods Sold | 12,290 | 12,535 | 9,383 | 9,919 | 7,625 | 20,364 | 14,161 | 17,047 |
| Gross Profit | 41,254 | 45,087 | 49,383 | 52,553 | 49,711 | 26,133 | 23,267 | 26,601 |
| Operating Expenses | ||||||||
| Research & Development | 14,807 | 26,648 | 14,944 | 11,013 | 9,754 | 11,787 | 8,487 | 7,647 |
| Sales General & Admin | 30,436 | 26,089 | 29,094 | 26,555 | 25,742 | 27,674 | 26,516 | 26,917 |
| Total Operating Expenses | 45,950 | 53,640 | 44,934 | 38,464 | 36,197 | 40,439 | 35,772 | 35,326 |
| Operating Income (Loss) | (4,696) | (8,553) | 4,449 | 14,089 | 13,514 | (14,306) | (12,505) | (8,725) |
| Interest Income | ||||||||
| Interest Expense | ||||||||
| Other Expense | 3.00 | (117.00) | (10.00) | (28.00) | 213.00 | 55.00 | (17.00) | (39.00) |
| Pretax Income | (8,928) | (11,235) | 1,155 | 247.00 | 6,112 | (22,804) | (20,039) | (8,582) |
| Tax Provision | 126.00 | 615.00 | 0.00 | 0.00 | ||||
| Net Income (Loss) | (9,054) | (12,244) | 540.00 | 247.00 | 6,112 | (22,804) | (20,039) | (8,582) |
| Earnings Per Share (Basic) | (0.03) | (0.05) | 0.00 | 0.00 | 0.03 | (0.11) | (0.10) | (0.04) |
| Earnings Per Share (Diluted) | (0.03) | (0.05) | 0.00 | 0.00 | 0.03 | (0.11) | (0.10) | (0.04) |
| Weighted Average Shares Outstanding (Basic) | 267,047 | 257,158 | 264,786 | 262,566 | 235,498 | 210,947 | 210,348 | 209,705 |
| Weighted Average Shares Outstanding (Diluted) | 267,047 | 257,158 | 274,373 | 271,104 | 241,603 | 210,947 | 210,348 | 209,705 |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About AKBA
Akebia Therapeutics, Inc. (NASDAQ: AKBA) is a stock listed on the Nasdaq Stock Market under the ticker symbol AKBA. It last traded at $0.6800 (Oct 19, 2026, 4:00 PM ET), up 1.5% on the day. That gives Akebia Therapeutics a market capitalisation of $185.7M.
Over the past 52 weeks AKBA has traded between $0.6700 and $3.20.
Revenue for the quarter ended Mar 31, 2026 was $53.5M; a net loss of $9.1M. Revenue was down 6.6% from $57.3M in the quarter ended Mar 31, 2025.
| Quarter ended | Revenue | Net income | Margin |
|---|---|---|---|
| Mar 31, 2026 | $53.5M | -$9.1M | -16.9% |
| Dec 31, 2025 | $57.6M | -$12.2M | -21.2% |
| Sep 30, 2025 | $58.8M | $540.0K | 0.9% |
| Jun 30, 2025 | $62.5M | $247.0K | 0.4% |
From Akebia Therapeutics’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…